Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial

References

• Ribaldone DG, Zurlo C, Fagoonee S, et al. A retrospective experience of Helicobacter pylori histology in a large sample of subjects in Northern Italy. Life (Basel). 2021;11(7):650.
   PubMed Web of Science ®Google Scholar
• Walsh JH, Peterson WL. The Treatment of Helicobacter pylori Infection in the management of peptic ulcer disease. N Engl J Med. 1995;333(15):984–991.
   PubMed Web of Science ®Google Scholar
• Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378(12):1085–1095.
   PubMed Web of Science ®Google Scholar
• Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69(12):2093–2112.
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–1153.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim N, Nam RH, et al. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24(2):e12561.
   PubMed Web of Science ®Google Scholar
• Woo HY, Park DI, Park H, et al. Dual-Priming Oligonucleotide-Based Multiplex PCR for the detection of helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens. Helicobacter. 2009;14(1):22–28.
   PubMed Web of Science ®Google Scholar
• Cho JH, Jin SY. Optimized diagnosis of Helicobacter pylori and tailored eradication therapy for preventing gastric cancer: a proposal for SHAKE strategy. Expert Rev Gastroenterol Hepatol. 2020;14(7):553–564.
   PubMed Web of Science ®Google Scholar
• Cho JH, Jeon SR, Kim HG, et al. Cost-effectiveness of a tailored Helicobacter pylorieradication strategy based on the presence of a 23Sribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. J Gastroenterol Hepatol. 2019;34(4):700–706.
   PubMed Web of Science ®Google Scholar
• Choe JW, Jung SW, Kim SY, et al. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter. 2018;23(2):e12466.
   PubMed Web of Science ®Google Scholar
• Bang CS, Lim H, Jeong HM, et al. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes. 2020;11(5):1314–1323.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim JI, Cheung DY, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013;208(7):1123–1130.
   PubMed Web of Science ®Google Scholar
• Cho JH, Jeon SR, Kim HG, et al. Factors for improving the diagnostic efficiency of the rapid urease test from the gastric corpus. Scand J Gastroenterol. 2017;52(12):1320–1325.
   PubMed Web of Science ®Google Scholar
• Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pyloriinfection. J Gastroenterol Hepatol. 2009;24(10):1587–1600.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102(2):493–496.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Chalmers DM, Axon AT. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol. 1997;32(1):24–27.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275–278.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53(3):354–361.
   PubMed Web of Science ®Google Scholar
• Gong EJ, Yun SC, Jung HY, et al. Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: is It Time to Change? J Korean Med Sci. 2014;29(5):704–713.
   PubMed Web of Science ®Google Scholar
• Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109(10):1595–1602.
   PubMed Web of Science ®Google Scholar
• Zullo A, Hassan C, Lorenzetti R, et al. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis. 2003;35(5):357–361.
   PubMedGoogle Scholar
• Lee JH, Ahn JY, Choi KD, et al. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: a prospective multicenter study. Helicobacter. 2019;24:e12592.
   PubMed Web of Science ®Google Scholar
• Isaeva G, Isaeva R. Molecular methods for the detection of Helicobacter pylori. Minerva Biotecnologica. 2020;32:182–187.
   Web of Science ®Google Scholar
• Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006;6(11):699–709.
   PubMed Web of Science ®Google Scholar
• Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol. 2010;44:536–543.
   PubMed Web of Science ®Google Scholar
• Wang YH, Li Z, Wang L, et al. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori. Helicobacter. 2018;23:e12467.
   PubMed Web of Science ®Google Scholar
• Jung HK, Kang SJ, Lee YC, et al. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15(2):168–195.
   PubMed Web of Science ®Google Scholar
• Ong S, Kim SE, Kim JH, et al. Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: a multicenter randomized controlled trial. Helicobacter. 2019;24(5):e12654.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim N, Kim JM, et al. Prevalence of Primary and Secondary Antimicrobial Resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18(3):206–214.
   PubMed Web of Science ®Google Scholar
• Kim YI, Lee JY, Kim CG, et al. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol. 2021;21(1):95.
   PubMed Web of Science ®Google Scholar
• Choi YI, Chung JW, Park DK, et al. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylorieradication: a comparative, open trial. World J Gastroenterol. 2019;25(46):6743–6751.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am. 2015;44(3):537–563.
   PubMed Web of Science ®Google Scholar
• Nyssen OP, Perez-Aisa A, Tepes B, et al. Hp-EuReg Investigators. Adverse event profile during the treatment of Helicobacter pylori: a real-world experience of 22,000 patients from the European Registry on H. pylori management (Hp-EuReg). Am J Gastroenterol. 2021;116(6):1220–1229.
   PubMed Web of Science ®Google Scholar
• Al-Eidan FA, McElnay JC, Scott MG, et al. Management of Helicobacter pylorieradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002;53(2):163–171.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Yang CH, Song HJ, et al. Online registry for nationwide database of Helicobacter pylorieradication in Korea: correlation of antibiotic use density with eradication success. Helicobacter. 2019;24(5):e12646.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pyloritherapy. Gut. 2015;64(11):1715–1720.
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylorieradication therapies. Expert Rev Anti Infect Ther. 2018;16(9):679–687.
   PubMed Web of Science ®Google Scholar
• McNicholl AG, Bordin DS, Lucendo A, et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol. 2020;18(1):89–98.
   PubMed Web of Science ®Google Scholar
• Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylorieradication with triple therapy. Gut. 2016;65(5):870–878.
   PubMed Web of Science ®Google Scholar
• Ko SW, Kim YJ, Chung WC, et al. Bismuth supplements as the first-line regimen for Helicobacter pylorieradication therapy: systemic review and meta-analysis. Helicobacter. 2019;24(2):e12565.
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhang W, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol. 2016;111(12):1736–1742.
   PubMed Web of Science ®Google Scholar
• Nyssen OP, Perez-Aisa A, Castro-Fernandez M, et al. European Registry on Helicobacter pylorimanagement: single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J. 2021;9(1):38–46.
   PubMed Web of Science ®Google Scholar